GeneDx (NASDAQ:WGS) PT Raised to $15.00

GeneDx (NASDAQ:WGS) had its price objective lifted by BTIG Research from $11.00 to $15.00 in a research report report published on Monday, Benzinga reports. BTIG Research currently has a buy rating on the stock.

Separately, The Goldman Sachs Group lifted their price objective on GeneDx to $11.00 and gave the stock a neutral rating in a research note on Monday, April 15th.

GeneDx Price Performance

WGS opened at $11.82 on Monday. The stock has a market cap of $307.91 million, a price-to-earnings ratio of -1.59 and a beta of 2.75. GeneDx has a 1 year low of $1.16 and a 1 year high of $12.57. The company has a current ratio of 3.10, a quick ratio of 2.95 and a debt-to-equity ratio of 0.23. The stock has a fifty day moving average price of $9.02 and a 200 day moving average price of $4.91.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.01. The firm had revenue of $57.42 million during the quarter, compared to analysts’ expectations of $57.00 million. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. Analysts forecast that GeneDx will post -2.02 EPS for the current fiscal year.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc acquired 40,000 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were bought at an average cost of $8.74 per share, with a total value of $349,600.00. Following the completion of the acquisition, the director now owns 2,702,609 shares of the company’s stock, valued at $23,620,802.66. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other GeneDx news, Director Casdin Capital, Llc bought 40,000 shares of GeneDx stock in a transaction dated Monday, March 4th. The shares were acquired at an average cost of $8.74 per share, with a total value of $349,600.00. Following the acquisition, the director now directly owns 2,702,609 shares of the company’s stock, valued at $23,620,802.66. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Feeley sold 3,253 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $10.59, for a total value of $34,449.27. Following the completion of the transaction, the chief financial officer now directly owns 28,927 shares in the company, valued at $306,336.93. The disclosure for this sale can be found here. Insiders have sold 13,820 shares of company stock worth $146,354 over the last three months. Company insiders own 28.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. PFG Investments LLC bought a new stake in shares of GeneDx during the 1st quarter valued at $95,000. Thompson Davis & CO. Inc. increased its position in shares of GeneDx by 99.4% in the 4th quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock valued at $55,000 after buying an additional 9,944 shares in the last quarter. Pathstone Family Office LLC boosted its stake in GeneDx by 262.2% in the 3rd quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after purchasing an additional 39,327 shares during the period. Decheng Capital LLC acquired a new position in GeneDx in the 4th quarter worth $285,000. Finally, Trellus Management Company LLC boosted its stake in GeneDx by 55.0% in the 3rd quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after purchasing an additional 54,976 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.